A detailed history of Ensign Peak Advisors, Inc transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 63,874 shares of VIR stock, worth $454,782. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,874
Previous 50,274 27.05%
Holding current value
$454,782
Previous $447,000 6.94%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.26 - $10.7 $98,736 - $145,520
13,600 Added 27.05%
63,874 $478,000
Q1 2024

May 14, 2024

SELL
$8.6 - $11.9 $21,809 - $30,178
-2,536 Reduced 4.8%
50,274 $509,000
Q4 2023

Feb 14, 2024

BUY
$7.76 - $10.29 $176,928 - $234,611
22,800 Added 75.97%
52,810 $531,000
Q3 2023

Nov 13, 2023

SELL
$9.14 - $24.62 $1.35 Million - $3.64 Million
-147,691 Reduced 83.11%
30,010 $281,000
Q1 2023

May 15, 2023

BUY
$22.26 - $30.85 $1.41 Million - $1.96 Million
63,511 Added 55.62%
177,701 $4.14 Million
Q4 2022

Feb 13, 2023

BUY
$19.96 - $28.22 $146,706 - $207,417
7,350 Added 6.88%
114,190 $2.89 Million
Q3 2022

Nov 14, 2022

BUY
$18.26 - $31.1 $696,637 - $1.19 Million
38,151 Added 55.54%
106,840 $2.06 Million
Q2 2022

Aug 12, 2022

SELL
$19.08 - $26.7 $855,165 - $1.2 Million
-44,820 Reduced 39.49%
68,689 $1.75 Million
Q1 2022

May 16, 2022

BUY
$21.19 - $40.01 $62,298 - $117,629
2,940 Added 2.66%
113,509 $2.92 Million
Q4 2021

Feb 11, 2022

BUY
$30.97 - $54.03 $3.42 Million - $5.97 Million
110,569 New
110,569 $4.63 Million
Q4 2020

Feb 12, 2021

SELL
$25.51 - $43.38 $615,505 - $1.05 Million
-24,128 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$28.28 - $53.6 $525,385 - $995,780
18,578 Added 334.74%
24,128 $829,000
Q2 2020

Aug 12, 2020

BUY
$27.89 - $47.86 $154,789 - $265,623
5,550 New
5,550 $227,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $944M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.